-
O-arm stereotactic imaging in deep brain stimulation surgery workflow: A utility and cost-effectiveness analysis
-
Object and action naming test in cognitive subtypes in nondemented patients with Parkinson´s disease
-
Objective measurement of limb bradykinesia using marker-less tracking algorithm with 2D-video of PD patients
-
Objective Measurement of Muscle Mechanical Properties using a Myometric Device in People with Parkinson’s Disease in a Clinical Setting in Africa
-
Objective study of intra operative test for discovering optimal electrode site for effective imaging and bilateral STN-DBS stereotactic functional neurosurgery
-
Obsessive-Compulsive Characteristics in Adult Tourette Syndrome Patients with and without OCD
-
Odor Identification as a Biomarker of Incident Cognitive Impairment and its Correlation with Neuropathology in the Rush MAP
-
Olfactory dysfunction and its relationship with clinical features of Parkinson’s disease
-
Olfactory impairment in Wilson’s disease
-
On Time, Every Time: The Effect of Cohort Ward Triage, Specialist Nursing & Admission Pre-Alert on Parkinson’s Medication Management
-
On-Demand Treatment Preferences of Patients with Parkinson’s Disease and “OFF” Episodes: Heterogeneity Across Patient Subgroups
-
Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis
-
Open data sharing of the Parkinson’s Outcomes Project: A global, longitudinal clinical study of over 13,000 people with Parkinson’s disease
-
Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease
-
Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis
-
Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study
-
Opicapone in fluctuating Parkinson’s disease: The daily clinical practice
-
Opicapone in Parkinson’s disease – a centre’s real-life experience
-
Opicapone management: A 2-year follow up real- life practice study
-
Opicapone study in daily clinical practice. OPRA study
-
Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II
-
Optic atrophy and parkinsonism in a family associated with OPA1 mutation
-
Oral treatment of the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS) with the neuro-inflammation inhibiting compound PRI-003
-
Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics
-
Orthostatic hypotension in early onset Parkinson’s disease
-
Orthostatic hypotension in Parkinson’s disease
-
Outcome Profiles in Advanced Parkinson’s Disease Patients Treated With Long-Term Levodopa-Carbidopa Intestinal Gel in a Routine Clinical Practice: Analysis From the COSMOS Study
-
Outcomes of a Prospective, Multicenter, International Registry of Deep Brain Stimulation for Parkinson’s Disease
-
Overcoming Stimulation-Related Side Effects And Improving Outcome By Proper Programing Of Subthalamic Stimulation Of Parkinson’s Disease: Cases Report
MDS Virtual Congress 2020
September 12-16, 2020. Virtual Congress. www.mdscongress.org